Adamas Pharmaceuticals to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 15 2016 - 4:05PM
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced
that Gregory T. Went, Ph.D., Chairman and Chief Executive
Officer of Adamas, will present at the Piper Jaffray Healthcare
Conference in New York on Tuesday, November 29, 2016 at 9:30 a.m.
Eastern Time.
The presentation will be webcast live from the
investor relations section of the Adamas website
at http://ir.adamaspharma.com/events.cfm and available
for approximately two weeks.
About Adamas Pharmaceuticals,
Inc. Adamas is a pharmaceutical company that is developing
new medicines to improve the daily lives of those affected by
chronic neurologic disorders, including Alzheimer’s disease,
Parkinson’s disease, multiple sclerosis, and epilepsy. Adamas
has pioneered a platform based on an understanding of time
dependent biologic effects of disease activity and drug response to
achieve symptomatic relief without additional tolerability
issues. We have developed a portfolio of chrono-synchronous
therapies to potentially address chronic neurologic
disorders. Our lead program, ADS-5102 in development for the
treatment of levodopa-induced dyskinesia (LID) in patients with
Parkinson’s disease, is currently being evaluated by the U.S. Food
and Drug Administration (FDA) for potential approval in 2017.
ADS-5102 has additional opportunities to potentially provide
symptomatic treatment of other chronic neurologic disorders such as
multiple sclerosis walking impairment and several other
indications. Our newest clinical development program,
ADS-4101, is entering the clinic for the improved control of
epileptic seizures. Additionally, through our license
agreement with Forest Laboratories Holding Ltd. (a wholly owned
subsidiary of Allergan plc), the company is eligible to receive
royalties on sales of NAMENDA XR® and NAMZARIC® beginning in June
of 2018 and May of 2020, respectively. For more information,
please visit www.adamaspharma.com.
NAMENDA XR® and NAMZARIC® are registered trademarks
of Merz Pharma GmbH & Co. KGaA.
Martin Forrest
VP Corporate Communications and Investor Relations
510-450-3528
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2023 to Apr 2024